Established in 2000, The Yates Network consists of a core team of bioscience communications veterans, each with approximately 20 years of experience. Unlike other communications firms, The Yates Network provides clients with day-to-day service from only the most highly experienced professionals. This ensures that our client service is focused on the things that matter: sharp strategy, targeted messaging, and results-driven communications programs that are efficient and effective.
Barbara Yates established The Yates Network in 2000 with the aim to establish a consultancy to bring strategic communications ideas, media visibility, and passion to biotech companies who possess the science and people to make a major impact for patients. Barbara has 20 years of communications experience in roles as an internal corporate communications leader and as an external consultant – but, always with high-growth and start-up companies.
Barbara offers biotech clients a broad range of expertise and a vast professional network from her work in communications to the media, investors, regulators, physicians, and patient advocacy groups. She brings to a project team the unique ability to develop or enhance a strategy, and then fully integrate it with high-impact tactics and programs that achieve business results.
In her decade as a consultant, Barbara has worked for a wide range of clients from biotech companies, both private and public, as well as big pharma companies, like Pfizer and Astra Zeneca. Clients view her as a trusted advisor and team leader in ‘game changing’ scientific and business news, such as journal publications in Nature, JAMA, and NEJM; major partnering deals; and IPOs. Her experience spans most all therapeutic areas including oncology, CV, mental illness, neurological diseases, HIV/AIDs, infectious disease, endocrinology/metabolic disease, diabetes, inflammation, and rare disorders.
Prior to founding The Yates Network, Barbara served as Vice President of corporate communications in the US for Serono, Inc., as it emerged to become a major biotech company with multiple blockbusters and more than $1 billion in global product sales. With responsibility for Serono’s US public relations in all therapeutic areas, including multiple sclerosis, reproductive health, and HIV/AIDS, Barbara managed programs for media relations, patient advocacy relations, medical meetings and publications, and clinical trial communications.
Barbara has a BA from Cornell University. She earned a Masters of Business Administration (MBA) and Masters of Public Health (MPH) from Boston University.
Kathryn Morris has more than 20 years of agency and corporate public relations experience. She has helped biotech companies reach their target audiences by connecting with reporters, building relationships with key publications and working the phones and e-mail to pitch news.
Kathryn's media strategy and pitching projects have helped launch products and position companies for a multitude of high-visibility biotech clients. Kathryn has played a leadership role in the media outreach plans and placement for biotech and health care firms that include Alnylam, Momenta, Alkermes, Sirtris, Ortho McNeil, Novartis, National Women's Health Resource Center, Amgen, Janssen, Serono, and Celgene.
The hallmark of Kathryn’s professional expertise is her strong rapport with media of all types, from the newswires and newsweeklies, to national newspapers, business publications, morning shows, news programs, and a variety of online media.
Earlier in her career, Kathryn built her base of media relations experience as a PR professional with Burson-Marsteller. Kathryn earned a bachelor of journalism degree from the University of Missouri, cum laude.
Mary Moynihan applies more than 25 years of focused work in bioscience communications, journalism, and publication and graphic design to provide strategy, text and graphic content development, and website development expertise to clients of The Yates Network.
Mary has extensive experience working closely with biotech entrepreneurs and understands the unique challenges science-based startups face in developing corporate positioning and value propositions for products with long development timelines; keeping pace with shifting regulations on drug research; maximizing yield from limited resources; and winning the support of business, investor, and scientific audiences.
Mary’s past experience includes service as a PR/communications consultant to dozens of biotechnology companies and select research institutions. Prior to that, she was founding director of communications for the University of Maryland Biotechnology Institute, where she led public relations for the institute's mission to advance basic research while partnering with industry to apply research in the areas of new drug development, protein engineering, agricultural biotechnology, and marine biotechnology. Earlier in her career, Mary served in corporate communications positions as well as editing positions at national and regional publications, developing expertise in communications strategy, positioning and message development, the practice of media relations from "both sides of the desk,” graphic design and typography, publication design and production, state legislative communications, and speechwriting.
Gina is a communications professional with more than 15 years experience in the development of strategic communications programs within the biotechnology industry. Specific skill sets include corporate communications, investor relations, marketing communications, public relations, advocacy and community relations.
Gina has developed and implemented broad communications programs across a variety of key audiences, supported the launch of five breakthrough biotechnology products and counseled senior management and managed communications issues around significant strategic shifts.
Gina has held senior roles within both early-stage and established biotechnology companies including Senior Director of Investor Relations and Corporate Communications at Millennium Pharmaceuticals, Vice President of Corporate Communications for CombinatoRx and various communications roles at Wyeth Research.
She earned an M.S. in Communications Management from Simmons College and a B.A. in Marketing Management from Northeastern University. Gina is an active member of the Healthcare Business Women’s Association, the National Investor Relations Institute and the Massachusetts Biotechnology Council.